Topic: Qnexa
NEW YORK (Reuters Health) - An experimental diet drug seems to help some obese people shed pounds, and keep them off for two years, researchers report.The drug, which will be called Qnexa if it reaches the market, is a combination of the ...
Biotech company Arena awaits the Food and Drug Administration's (FDA) approval of Lorcaserin, while Vivus waits for FDA approval of the drug Qnexa, and Orexigen waits for their contender in the obesity war, Contrave, to be approved.. The history of the weight-reduction ...
Just days after denying approval of Arena Pharmaceuticals' (ARNA) lorcaserin to treat obesity, the U.S. Food and Drug Administration notified Vivus (VVUS) it would not approve its application to market its experimental obesity drug Qnexa (phentermine/topiramate) without additional information. Vivus had sought ...
Just days after denying approval of Arena Pharmaceuticals' (ARNA) lorcaserin to treat obesity, the U.S. Food and Drug Administration notified Vivus (VVUS) it would not approve its application to market its experimental obesity drug Qnexa (phentermine/topiramate) without additional information. Vivus had sought ...
FDA's complete response letter on Qnexa was probably the best Vivus (VVUS) could have hoped for. (Vivus sheds more weight after Adcom rejection of Qnexa, July 16, 2010). The only mystery left was what the FDA would ask of Vivus. Instead, the ...
The U.S. Food and Drug Administration's rejection of Arena's (ARNA) experimental obesity drug lorcaserin now shifts public attention to two other contenders set to come before the agency for review. Even a more modest evaluation put forth by Vivus (VVUS), developer of ...
MO, Oct. 7 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA , an investigational drug candidate, are highlighted in six poster presentations at the 28th Annual Scientific Meeting of The Obesity Society, being held October 8-12, 2010 in ...
That's the promise of the experimental weight loss drug Qnexa, according to its developer, Vivus (VVUS). Illustrating Qnexa's safety and efficacy to the U.S. Food and Drug Administration is Vivus' top concern as it races to dispel concerns about the drug's risks ...
Vivus announced last week what I am sure they wish they could have announced prior to the FDA panel meeeting in July--the results of a two year study monitoring 675 obese or overweight patients using the company's Qnexa drug, showing an average ...
Vivus Inc. (VVUS) recently announced positive data from a two-year trial of its weight loss, once-daily pill Qnexa. The FDA panel's recommendation was based on the results of the 56-week CONQUER trial, in which Qnexa though found efficacious for weight loss, triggered ...
From Around the Web
Video Gallery
-
Drugs for Obesity; Weight-loss drug Qnexa ...
New Drugs for obesity Old phenteramine like Subutramine Meridia 5-10 ...2010-07-14 -
Qnexa, a New Weight Loss Drug ...
In this video news segment, Dr. Karon LoCicero, LMG Medical ...2010-07-16 -
QNEXA Review - Dietspotlight.com
dietspotlight.com begins its review of QNexa by noting that ...2011-09-07
